Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Natera, Inc. - Common Stock
(NQ:
NTRA
)
351.14
+9.35 (+2.74%)
Streaming Delayed Price
Updated: 3:51 PM EDT, Sep 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Natera, Inc. - Common Stock
< Previous
1
2
...
17
18
19
20
21
22
23
24
Next >
New Natera Data to be Presented at the 2023 ASCO Annual Meeting in 13 Studies Across Multiple Cancer Types
May 30, 2023
From
Natera, Inc.
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
↗
May 26, 2023
Via
Benzinga
Jury Rules in Favor of Natera, Finding all Asserted Patents Valid and Infringed by ArcherDX/Invitae; Awards $19.35 Million in Past Damages for Royalties and Lost Profits
May 15, 2023
From
Natera, Inc.
Via
Business Wire
The Latest Analyst Ratings for Natera
↗
March 03, 2023
Via
Benzinga
Natera's Earnings Outlook
↗
February 27, 2023
Via
Benzinga
Why Natera Stock Is Leading Its Industry Group With A 17% Jump Today
↗
February 16, 2023
Natera snagged a key win that could help extend its patient pool.
Via
Investor's Business Daily
Natera Reports First Quarter 2023 Financial Results
May 09, 2023
From
Natera, Inc.
Via
Business Wire
Natera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
May 08, 2023
From
Natera, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2023
↗
May 05, 2023
Via
Benzinga
Natera Announces First Quarter 2023 Earnings Conference Call
May 02, 2023
From
Natera, Inc.
Via
Business Wire
Natera Announces New Signatera™ MRD Data at 2023 AACR Annual Meeting
April 14, 2023
From
Natera, Inc.
Via
Business Wire
New Publication Demonstrates Utility of Natera’s Signatera™ Test in Melanoma
March 22, 2023
From
Natera, Inc.
Via
Business Wire
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
↗
March 15, 2023
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.
Via
InvestorPlace
Catalent Stock Showing Improved Relative Strength Rating
↗
March 10, 2023
On Friday, Catalent stock earned a positive adjustment to its Relative Strength (RS) Rating, from 63 to 74.
Via
Investor's Business Daily
Natera Announces Commercial Payor Coverage for Signatera™
March 02, 2023
From
Natera, Inc.
Via
Business Wire
Natera Reports Fourth Quarter and Full Year 2022 Financial Results
February 28, 2023
From
Natera, Inc.
Via
Business Wire
Earnings Scheduled For February 28, 2023
↗
February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter.
Via
Benzinga
Natera to Participate in Upcoming Investor Conferences
February 24, 2023
From
Natera, Inc.
Via
Business Wire
Natera Appoints Ruth E. Williams-Brinkley to its Board of Directors
February 23, 2023
From
Natera, Inc.
Via
Business Wire
Natera Announces Fourth Quarter and Fiscal 2022 Earnings Conference Call
February 21, 2023
From
Natera, Inc.
Via
Business Wire
Why Boston Beer Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
February 16, 2023
Gainers TravelCenters of America Inc. (NASDAQ: TA) shares jumped 70.5% to $84.32 after BP announced it will acquire the company for $86 per share in cash.
Via
Benzinga
KBR, Twilio, Roku And Other Big Stocks Moving Higher On Thursday
↗
February 16, 2023
U.S. stocks traded lower, with the Dow Jones dropping over 250 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Breast Cancer
February 16, 2023
From
Natera, Inc.
Via
Business Wire
New Paper Highlights Clinical Utility of Natera’s Renasight™ Test in the Management of Kidney Disease
February 02, 2023
From
Natera, Inc.
Via
Business Wire
New Signatera™ MRD Data in Gastrointestinal Cancers to be Presented at the ASCO GI Symposium 2023
January 19, 2023
From
Natera, Inc.
Via
Business Wire
Raymond James Upgrades Natera & Myriad Genetics, While Downgrading This Stock
↗
January 18, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023
↗
January 18, 2023
Via
Benzinga
Natera Announces Publication of Prospective, Multi-Site CIRCULATE Study in Nature Medicine Demonstrating Signatera’s Ability to Predict Chemotherapy Benefit in Colorectal Cancer
January 17, 2023
From
Natera, Inc.
Via
Business Wire
Natera to Webcast Live Presentation at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Natera, Inc.
Via
Business Wire
Natera Supports Updated ISHLT Guidelines for the Care of Heart Transplant Patients
December 21, 2022
From
Natera, Inc.
Via
Business Wire
< Previous
1
2
...
17
18
19
20
21
22
23
24
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
